皮质类固醇用于治疗莱普托斯皮罗斯症
Nathaniel Lee1,2, Su Myat Han1,3, Patrick Mukadi4,5,6
1School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
The Cochrane database of systematic reviews
|July 24, 2025
概括
这次审查发现对瘦皮质类固醇治疗的证据确定性非常低,这意味着它们的益处和危害仍然不确定. 需要更多高质量的随机试验来指导这种细菌感染的治疗决策.
科学领域:
- 传染性疾病 传染性疾病
- 细菌学 细菌学是一门学科.
- 临床试验 临床试验
背景情况:
- 莱普托斯皮罗斯是一种由Leptospira spp.引起的动物性细菌性疾病.
- 皮质类固醇有时用于严重的白病,但其疗效尚不清楚.
- 本综述评估了从随机试验中获得的关于皮质类固醇在白病中使用的证据.
研究的目的:
- 为了评估皮质类固醇的益处和危害,与安慰剂或标准护理对白病治疗.
- 综合来自对皮质类固醇干预的随机临床试验的发现.
主要方法:
- 随机对照试验的系统审查和元分析.
- 搜索了多个数据库,包括Cochrane,MEDLINE和Embase,直到2025年4月.
- 包括试验评估皮质类固醇对于白病,无论类型,剂量或参与者特征.
主要成果:
- 包括253名参与者的4项试验,所有这些都存在偏见或一些担忧的高风险.
- 非常低的确定性证据表明,皮质类固醇可能对死亡率或严重不良事件几乎没有影响.
- 关于非严重不良事件,住院时间和Jarisch-Herxheimer反应的证据不确定.
结论:
- 目前的证据不足以确定皮质类固醇对皮质螺旋体的疗效或安全性.
- 缺乏协调的策略,结果定义和严格的试验,阻碍了治疗指导.
- 未来的研究应该专注于精心设计的随机试验,以解决这些证据缺口.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
01:30Bacterial Phylum Spirochaetes
117
Spirochetes, unique bacteria in the phylum Spirochaetes, are gram-negative, motile, tightly coiled, slender, and flexible. They inhabit aquatic sediments and animals, with some causing diseases like syphilis. Spirochetes are classified into eight genera based on habitat, pathogenicity, phylogeny, and characteristics.Their distinctive motility arises from endoflagella, located within the cell’s periplasm. These endoflagella anchor at the cell poles and extend along the cell length, encased...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:14Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
01:26Nephrotic Syndrome II : Assessment and Medical Management
23
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
23
01:26COPD: Management Using Bronchodilators and Corticosteroids
314
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
314